Crispr Therapeutics shares tumble after significant earnings miss
LONDON - Xaar PLC, a leader in industrial inkjet technology, has disclosed the granting of share awards to key executives as part of its Long Term Incentive Plan (LTIP). On Tuesday, the company awarded shares to three top figures, including two executive directors and one person discharging managerial responsibilities (PDMR).
Executive Director John Mills was awarded 612,791 shares, while fellow Executive Director Paul James received 373,878 shares. PDMR Graham Tweedale was granted 166,151 shares. The share awards were calculated based on a price of £1.003 per share, reflecting the average closing price from May 1 to May 2, 2025.
These awards are contingent upon the achievement of specific performance conditions over a three-year period ending on December 31, 2027, followed by a two-year holding period for the executive directors. The performance measures include adjusted profit before tax (aPBT), revenue, and total shareholder return (TSR) relative to a comparator group. The company has stated that the performance targets related to aPBT and revenue are considered commercially sensitive and will be disclosed retrospectively, as has been done in previous years. However, the TSR performance condition remains consistent with the criteria set for the 2024 awards, as detailed in the company’s annual report for that year.
The information regarding these transactions was released in compliance with the UK Market Abuse Regulation and is part of a regulatory announcement that fulfills the company’s transparency obligations.
This announcement is based on a press release statement and aims to provide shareholders and the market with factual information regarding the incentive plan and its potential impact on the company’s leadership and performance. It does not endorse the company’s strategy or the potential benefits of the incentive plan.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.